21 September 2012
EMA/611488/2012
Human Medicines Development and Evaluation

Public statement on

Rivastigmine Teva (rivastigmine)

Withdrawal of the marketing authorisation in the European Union

On the 17 April 2009 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Rivastigmine Teva (Rivastigmine) which was approved for the symptomatic treatment of patients with mild to moderately severe Alzheimer's dementia and symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

The marketing authorisation holder (MAH) responsible for Rivastigmine Teva was Teva Pharma B.V.

The European Commission was notified by a letter dated 24 August 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Rivastigmine Teva for commercial reasons. Rivastigmine Teva was only marketed in Romania.

On 10 September 2012 the European Commission issued a decision to withdraw the marketing authorisation for Rivastigmine Teva.

Pursuant to this decision the European Public Assessment Report for Rivastigmine Teva will be updated to reflect that the marketing authorisation is no longer valid.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8613
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union